Article Details

CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Buy at Zacks Investment Research

Retrieved on: 2021-02-24 23:59:47

Tags for this article:

Click the tags to see associated articles and topics

CytomX Therapeutics (NASDAQ:CTMX) Rating Increased to Buy at Zacks Investment Research. View article details on hiswai:

Excerpt

Acadian Asset Management LLC now owns 582,215 shares of the biotechnology company's stock worth $3,873,000 after acquiring an additional ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up